Genmab's acquisition of Merus for $8 billion enhances its oncology portfolio, promising growth and innovative therapies like ...
In today’s Pharmaceutical Executive Daily, we cover the impact of Novo Nordisk layoffs on its hometown in Denmark, GSK’s ...
AbbVie officially began construction on its new active pharmaceutical ingredient (API) manufacturing plant in North Chicago, ...
The founder of InflaRX discusses lessons learned during the COVID-19 pandemic and how they’re being applied in a ...
GSK appoints Luke Miels as CEO designate, set to lead the company into a pivotal growth phase starting January 2026.
The FDA has expanded Johnson & Johnson’s Tremfya (guselkumab) approval to children six years and older weighing at least 40 ...
While the MFN executive order targets drug companies for drug prices, Peter Rubin discusses how health plans also play a ...
AstraZeneca aims to harmonize its share listings globally to enhance sustainable growth and investor reach, maintaining headquarters in the UK. Enhertu shows superior outcomes in early-stage ...
Regeneron's Evkeeza gains FDA approval for treating young children with homozygous familial hypercholesterolemia, addressing ...
Eli Lilly halted a study on bimagrumab for Type 2 diabetes patients, focusing on weight loss and muscle mass preservation.
Crinetics Pharmaceuticals celebrates FDA approval of Palsonify, the first oral treatment for acromegaly, enhancing patient ...
Pharma leaders embrace direct-to-consumer strategies, with 94% exploring DTC programs to enhance patient experience and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback